Wedbush initiated coverage of Opus Genetics (IRD) with an Outperform rating and $8 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRD:
- Opus Genetics’ New Study on Vision Improvement: What Investors Need to Know
- Opus Genetics Advances Genetic Therapy for Rare Eye Conditions
- Opus Genetics Advances Gene Therapy for Retinal Degeneration: A Study Update
- Opus Genetics: Promising Gene Therapy Developments and Strategic Advancements Drive Buy Rating
- Opus Genetics initiated with a Buy at Chardan